PP167 Cost Effectiveness Of Universal Childhood Vaccination Against Hepatitis A. (December 2021)

• Record Type: Journal Article
• Authors: Valcarcel-Nazco, Cristina; Guirado-Fuentes, Carmen; García-Pérez, Lidia; Linertová, Renata; Mar, Javier; Limia-Sánchez, Aurora; Soler-Soneira, Marta; Varela-Martínez, Carmen; Serrano-Aguilar, Pedro
• Is Part Of: International journal of technology assessment in health care. Volume 37(2021)Supplement 1
• Page Start: 24
• Page End: 24
• Publication Date: 2021-12
• Subjects: Medical technology -- Periodicals; Technology assessment -- Periodicals; 610.28
• DOI: 10.1017/S0266462321001252
• Languages: English
• ISSNs: 0266-4623

Abstract

Abstract : Introduction: Hepatitis A (HA) is a liver disease with a low mortality rate, but it can cause debilitating symptoms and fulminant hepatitis in some cases. Its incidence is greater in geographical areas with poor sanitation and hygiene. Spain is considered a low-endemicity country, so universal childhood immunization against HA is currently not financed by the National Health System. The aim of this study was to synthesize the scientific evidence on the cost effectiveness of universal childhood vaccination against HA. Methods: Full economic evaluations, published in the English or Spanish languages, were included if they reported outcome measures related to the prevention of HA, adverse effects, or incremental cost-effectiveness ratios (ICERs). The Medline, Embase and Cochrane Library databases were searched for articles published from the beginning of the databases to April 2018. Results: A total of 23 economic evaluations were included: one in a country of high endemicity, nine in countries of intermediate endemicity, and 13 in countries with low endemicity. Only one Spanish study, published in 1997, was found. Studies conducted in high- and intermediate- endemicity countries concluded that a universal childhood vaccination program against HA was a cost-effective option. However, in the case of countries with low endemicity the results were heterogeneous, although most agreed that a systematic vaccination strategy would not be a cost-effective option and that the adoption of such a strategy would not be justified given the limited benefits it would offer. The results of the economic evaluations depended on parameters such as the price and duration of the vaccine effect and the program coverage. Conclusions: In countries with low endemicity the results were heterogeneous, although most studies concluded that the implementation of a universal vaccination strategy is not justified from the point of view of cost effectiveness.